Purple Biotech Net Worth
Purple Biotech Net Worth Breakdown | PPBT |
Purple Biotech Net Worth Analysis
Purple Biotech's net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Purple Biotech's financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Purple Biotech's overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Purple Biotech's net worth analysis. One common approach is to calculate Purple Biotech's market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Purple Biotech's stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Purple Biotech's net worth. This approach calculates the present value of Purple Biotech's future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Purple Biotech's cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Purple Biotech's net worth. This involves comparing Purple Biotech's financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Purple Biotech's net worth relative to its peers.
Enterprise Value |
|
To determine if Purple Biotech is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Purple Biotech's net worth research are outlined below:
| Purple Biotech had very high historical volatility over the last 90 days | |
| Net Loss for the year was (19.88 M) with loss before overhead, payroll, taxes, and interest of (120 K). | |
| Purple Biotech currently holds about 36.02 M in cash with (19.23 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.0. | |
| Purple Biotech has a frail financial position based on the latest SEC disclosures | |
| Latest headline from gurufocus.com: Purple Biotech Announces Closing of 2.8 Million Registered Direct Offering of American ... |
Purple Biotech Quarterly Good Will |
|
Purple Biotech uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Purple Biotech. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Purple Biotech's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 14th of February 2024 Upcoming Quarterly Report | View | |
| 21st of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 14th of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Know Purple Biotech's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Purple Biotech is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Purple Biotech backward and forwards among themselves. Purple Biotech's institutional investor refers to the entity that pools money to purchase Purple Biotech's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Sound Income Strategies | 2024-09-30 | 0.0 | Citadel Advisors Llc | 2024-09-30 | 0.0 | Millennium Management Llc | 2024-06-30 | 0.0 | Kingswood Wealth Advisors Llc | 2024-09-30 | 0.0 | Wealth Advisors Of Iowa, Llc | 2024-09-30 | 0.0 | Raymond James & Associates | 2024-09-30 | 0.0 | Xtx Topco Ltd | 2024-06-30 | 0.0 | Northwestern Mutual Wealth Management Co | 2024-06-30 | 0.0 | Hrt Financial Llc | 2024-09-30 | 0.0 | Armistice Capital, Llc | 2024-09-30 | 158 K | Virtu Financial Llc | 2024-06-30 | 19.3 K |
Follow Purple Biotech's market capitalization trends
The company currently falls under 'Nano-Cap' category with a current market capitalization of 6.7 M.Market Cap |
|
Project Purple Biotech's profitablity
| Last Reported | Projected for Next Year | ||
| Return On Capital Employed | 0.60 | 0.63 |
When accessing Purple Biotech's net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Purple Biotech's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Purple Biotech's profitability and make more informed investment decisions.
Please note, the imprecision that can be found in Purple Biotech's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Purple Biotech. Check Purple Biotech's Beneish M Score to see the likelihood of Purple Biotech's management manipulating its earnings.
Evaluate Purple Biotech's management efficiency
Purple Biotech has return on total asset (ROA) of (0.2925) % which means that it has lost $0.2925 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.4467) %, meaning that it created substantial loss on money invested by shareholders. Purple Biotech's management efficiency ratios could be used to measure how well Purple Biotech manages its routine affairs as well as how well it operates its assets and liabilities. Return On Capital Employed is likely to gain to 0.63 in 2024, whereas Return On Tangible Assets are likely to drop (0) in 2024. At this time, Purple Biotech's Non Current Liabilities Total is comparatively stable compared to the past year. Change To Liabilities is likely to gain to about 964.8 K in 2024, whereas Total Current Liabilities is likely to drop slightly above 3.7 M in 2024.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 0.15 | 0.15 | |
| Tangible Book Value Per Share | 0.03 | 0.03 | |
| Enterprise Value Over EBITDA | (0.27) | (0.29) | |
| Price Book Value Ratio | 0.59 | 0.49 | |
| Enterprise Value Multiple | (0.27) | (0.29) | |
| Price Fair Value | 0.59 | 0.49 | |
| Enterprise Value | 6.1 M | 11 M |
Purple Biotech's management has consistently demonstrated strong leadership, driving both financial growth and operational excellence. By analyzing current market trends and future growth opportunities, we assess the stock's true value and potential for investors.
Enterprise Value Revenue 33.0832 | Return On Equity (0.45) |
Purple Biotech Corporate Filings
6K | 6th of December 2024 A report filed by foreign private issuers with SEC. A foreign private issuer is a non-U.S. company with securities traded on U.S. exchanges. | ViewVerify |
| 4th of December 2024 Other Reports | ViewVerify | |
13A | 14th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
| 31st of July 2024 Other Reports | ViewVerify |
Purple Biotech Earnings per Share Projection vs Actual
Purple Biotech Corporate Management
| MA CPA | Chief Officer | Profile | |
| Fabien Sebille | Chief Officer | Profile | |
| Michael Schickler | Head Affairs | Profile | |
| LLM BSc | Vice Operations | Profile | |
| Ido Morpurgo | VP Operations | Profile | |
| Nir Livneh | VP Affairs | Profile |
Additional Tools for Purple Stock Analysis
When running Purple Biotech's price analysis, check to measure Purple Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Purple Biotech is operating at the current time. Most of Purple Biotech's value examination focuses on studying past and present price action to predict the probability of Purple Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Purple Biotech's price. Additionally, you may evaluate how the addition of Purple Biotech to your portfolios can decrease your overall portfolio volatility.